



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)



OPTIMIZING THE REFERRAL PROCESS

A guide to referring your patients to a pharmacy



Provide a strong recommendation

If your patient is eligible for a vaccine, your strong recommendation is a good way to help increase follow-through to vaccination.¹



Discuss patient expectations

Set expectations regarding the vaccine and walk patients through the process in clear language.

This includes:

- How it can help prevent shingles
- Information on administration, dosage, and potential adverse effects



Support your recommendation

Providing tangible information, including educational materials, or a prescription or eScript may encourage patients to take the next step toward vaccination.¹



Confirm vaccination appointment

Using a retail pharmacy app or the SHINGRIX vaccine scheduler to schedule appointments is a simple, efficient way to help ensure patients are getting vaccinated.



Follow up

Confirm and document their vaccination at your patient's next office visit to help reinforce the urgency of protection against shingles.¹

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX

Please see additional Important Safety Information for SHINGRIX on the back and accompanying full Prescribing Information.

PROVIDE CLEAR INFORMATION

Providing educational materials and an eScript may lead your patients to take the next step toward vaccination¹

HCPs may provide



PATIENT EDUCATION

Tear sheets that contain information on disease state, vaccination details, and scheduling guidance



A PRESCRIPTION

While not needed, an eScript or prescription is a helpful reminder to patients

How does vaccine information help?



Patients make informed decisions based on disease education



Patients receive vaccine reminders



Patients' sense of urgency around vaccination is elevated

Help your patients follow through on your recommendation



SCAN THE QR CODE TO SCHEDULE AN APPOINTMENT NOW AT SHINGRIX.COM

Ensure patients are scheduled for their vaccination appointment before leaving the office



HCP portrayal.

Important Safety Information (cont'd)

- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information for SHINGRIX on the front and accompanying full Prescribing Information.

HCP=healthcare professional.

Reference: 1. Centers for Disease Control and Prevention. Vaccine referral: a series on standards for adult immunization practice. Updated May 2016. Accessed July 19, 2023. <https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-referral.pdf>



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor.
SGXLBND230008 July 2023
Produced in USA. [0002-0025-70]